Protocols

Porges to Biogen: I don’t like your neuropathic pain drug; Ex-Moderna exec Bolen joins PureTech as CSO

Geoffrey Porges, Leerink

Geoffrey Porges, Leerink

Leerink’s Geoffrey Porges is pouring cold water over Biogen’s raxatrigine (BIIB074), a neuropathic pain drug it obtained in their $675 million deal to buy Convergence. Writes Porges: “We believe that Biogen’s neuropathic pain treatment candidate raxatrigine (BIIB074) faces long-odds due to the poor record of the class and troubling development history of this molecule; early signals are encouraging but at this stage we don’t see enough consistent evidence of benefit to add this to our model and value proposition for Biogen.”

Former Moderna R&D chief Joseph Bolen has joined Daphne Zohar’s PureTech as its CSO. Bolen, who also had a stint at Millennium, will now take his place at a company that’s routinely scouting for new biotech ideas to advance.

Shares of Puma Biotechnology $PBYI dipped after it announced plans to raise $150 million with a secondary offering. The biotech’s neratinib is currently under review at the FDA.

Sweden’s Neurovive has been struggling with Arbutus over the fate a hep B drug dubbed NVP018. But the confrontation is over now. Arbutus is returning its rights to the drug.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->